Article ; Online: Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak.
Medical oncology (Northwood, London, England)
2020 Volume 37, Issue 6, Page(s) 51
Abstract: As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of ... ...
Abstract | As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia. |
---|---|
MeSH term(s) | Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Lymphopenia/chemically induced ; Lymphopenia/mortality ; Neoplasms/complications ; Neoplasms/drug therapy ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; SARS-CoV-2 ; Temozolomide/adverse effects ; Temozolomide/therapeutic use |
Chemical Substances | Antineoplastic Agents, Alkylating ; Immunologic Factors ; Temozolomide (YF1K15M17Y) |
Keywords | covid19 |
Language | English |
Publishing date | 2020-04-24 |
Publishing country | United States |
Document type | Letter |
ZDB-ID | 1201189-7 |
ISSN | 1559-131X ; 0736-0118 ; 1357-0560 |
ISSN (online) | 1559-131X |
ISSN | 0736-0118 ; 1357-0560 |
DOI | 10.1007/s12032-020-01376-8 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1899: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.